Darbepoetin Alfa Injection Uses, Dosage, Side Effects and Interactions
Aranesp
Aranesp was the first darbepoetin alfa injection product the FDA approved, in 2001.
Darbepoetin alfa (Aranesp) is an injected erythropoiesis-stimulating agent (ESA) that treats anemia caused by chronic kidney disease or by chemotherapy in people with certain cancers.
Quick links
Ask Anything About Darbepoetin Alfa InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Darbepoetin Alfa Injection in Short
- Drug class Erythropoiesis-stimulating Agent How the FDA classifies it
What it treatsAranesp is used to treat anemia (low red blood cell levels) in two situations. The first is anemia from chronic kidney disease, in people on dialysis and people not on dialysis. The second is anemia caused by myelosuppressive chemotherapy (chemotherapy that suppresses the bone marrow) in people with non-myeloid…
- How you get it Prescription only
- Comes asInjection (into a vein, under the skin)Available strengths
- 10 mcg/0.4 mL
- 25 mcg/0.42 mL
- 40 mcg/0.4 mL
- 60 mcg/0.3 mL
- 100 mcg/0.5 mL
- 150 mcg/0.3 mL
See forms and strengths+ 3 more strengthsShow fewer strengths
- 200 mcg/0.4 mL
- 300 mcg/0.6 mL
Amount in each mL
- 40 mcg/mL
- The FDA’s strongest warningBoxed warning The FDA’s most serious alert. Read what it says
- What pharmacies pay
- Aranesp (brand)$186.12 to $1,500.15 per mL
- Most injection strengths about $446.91
The Pharmacist’s Take
Darbepoetin alfa (Aranesp) is a long-acting form of erythropoietin, the hormone that tells bone marrow to make red blood cells, used for anemia from chronic kidney disease or cancer chemotherapy; a familiar standby since about 2001, it is not available as a generic. Most people handle the shots well, and the side effect that matters most is rising blood pressure, sometimes with leg swelling. Its boxed warning says drugs in this class raise the risk of death, heart attack, stroke and blood clots, including in a dialysis access, and can speed tumor growth or return in cancer. The aim is the lowest dose that avoids transfusions, not a normal blood count.
Key Takeaways From the HelloPharmacist Team
- Expect a shot under the skin or into a vein, from weekly to every 4 weeks for kidney disease, or weekly or every 3 weeks during chemotherapy.
- Give it time, since hemoglobin usually takes 2 to 6 weeks to rise, and it has not been shown to ease fatigue.
- Get emergency help for chest pain, sudden weakness, trouble speaking, or a swollen painful leg, possible signs of heart attack, stroke or clot.
- Expect regular blood pressure, hemoglobin and iron checks, because the dose is adjusted to stay as low as possible.
FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Darbepoetin Alfa Injection.
Aranesp and other ESAs can increase the risk of death, heart attack, stroke, blood clots, clots in dialysis access, and tumor growth or return.
In chronic kidney disease, people had more deaths, serious heart problems, and strokes when treated to a hemoglobin above 11 g/dL. No dose or strategy has been shown to avoid these risks. The lowest dose that reduces the need for transfusions should be used.
In cancer, ESAs shortened survival and/or increased tumor progression or recurrence in studies of breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. Use only for anemia from chemotherapy, never when cure is the goal, and stop when the chemotherapy course ends.
Watch for chest pain, shortness of breath, leg swelling or pain, and sudden weakness, confusion or trouble speaking. Seek help right away if they occur.
Patient Information Guide for Darbepoetin Alfa Injection
What It’s Used For
Aranesp treats anemia in these settings:
- Anemia due to chronic kidney disease, in people on dialysis and not on dialysis (including children).
- Anemia due to chemotherapy in adults with non-myeloid cancers, when at least two more months of chemotherapy are planned.
It is not for cancer patients on hormonal agents, biologic products, or radiotherapy alone. It is also not for people whose chemotherapy aims at cure, or whose anemia can be managed by transfusion. It is not a substitute for transfusions when anemia needs immediate correction.
How It Works
Aranesp is an erythropoiesis-stimulating agent. It stimulates red blood cell production by the same mechanism as your body's own erythropoietin. This raises hemoglobin and lessens the need for transfusions.
Drug Class
Drug Class
- Erythropoiesis-stimulating Agent
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Erythropoiesis-stimulating Agent
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)None listed for Darbepoetin Alfa Injection in the FDA’s index.
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)- Increased Erythroid Cell Production
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)- Erythropoietin
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Other antianemic preparations
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Aranesp is injected into a vein or under the skin. How often depends on why you need it.
- Chronic kidney disease: from about weekly to monthly, depending on your situation. People on hemodialysis are generally given it into a vein.
- Chemotherapy-related anemia: under the skin, weekly or every 3 weeks, until the chemotherapy course ends.
Your doctor adjusts the dose based on hemoglobin checks, and may give iron. Follow your prescriber and the product label, and ask them what to do if you miss a dose.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Anemia from chronic kidney disease
Children under 18 years old · Starting dose Starting dose 0.45 mcg/kg once a week
- 0.45 mcg/kg body weight as a single subcutaneous or intravenous injection once weekly
Adults on dialysis · Starting dose · Weekly Starting dose 0.45 mcg/kg once a week
- 0.45 mcg/kg intravenously or subcutaneously as a weekly injection
Good to know
Intravenous route is recommended for patients on hemodialysis
Adults on dialysis · Starting dose · Every 2 weeks Starting dose 0.75 mcg/kg every 2 weeks
- 0.75 mcg/kg intravenously or subcutaneously once every 2 weeks as appropriate
Good to know
Intravenous route is recommended for patients on hemodialysis
Adults not on dialysis · Starting dose Dose 0.45 mcg/kg
- 0.45 mcg/kg body weight intravenously or subcutaneously given once at four week intervals as appropriate
People on dialysis · Starting dose Starting dose 0.75 mcg/kg every 2 weeks
- 0.75 mcg/kg once every 2 weeks
Good to know
Patients not receiving dialysis may be initiated at this dose
Adults and children on dialysis switching from epoetin alfa · Less than Dose 6.25 mcg/week
- Adult: 6.25 mcg/week
- Pediatric: * (data insufficient to determine an Aranesp conversion dose)
Good to know
Given once weekly if on epoetin alfa 2 to 3 times weekly; once every 2 weeks if on epoetin alfa once weekly
Adults and children on dialysis switching from epoetin alfa · 6.25 mcg Starting dose 6.25 mcg a week
Step by step
- Adult: 6.25 mcg/week
- Pediatric: 6.25 mcg/week
Adults and children on dialysis switching from epoetin alfa · 12.5 mcg/week Dose 12.5 mcg/week
Step by step
- Adult: 12.5 mcg/week
- Pediatric: 10 mcg/week
Adults and children on dialysis switching from epoetin alfa · 25 mcg/week Dose 25 mcg/week
Step by step
- Adult: 25 mcg/week
- Pediatric: 20 mcg/week
Adults and children on dialysis switching from epoetin alfa · 40 mcg Starting dose 40 mcg a week
Step by step
- Adult: 40 mcg/week
- Pediatric: 40 mcg/week
Adults and children on dialysis switching from epoetin alfa · 60 mcg Starting dose 60 mcg a week
Step by step
- Adult: 60 mcg/week
- Pediatric: 60 mcg/week
Adults and children on dialysis switching from epoetin alfa · 100 mcg Starting dose 100 mcg a week
Step by step
- Adult: 100 mcg/week
- Pediatric: 100 mcg/week
Adults and children on dialysis switching from epoetin alfa · 200 mcg Starting dose 200 mcg a week
Step by step
- Adult: 200 mcg/week
- Pediatric: 200 mcg/week
Anemia from cancer chemotherapy
For adults on chemotherapy · Weekly schedule
Starting dose 2.25 mcg/kg once a week
Step by step
- 2.25 mcg/kg every week subcutaneously until completion of a chemotherapy course
- Increase dose to 4.5 mcg/kg/week if hemoglobin increases by less than 1 g/dL and remains below 10 g/dL after 6 weeks
Good to know
Reduce dose by 40% if hemoglobin rises more than 1 g/dL in any 2-week period
Side Effects
Common side effects differ by condition.
Common side effects
- High blood pressure
- Shortness of breath
- Swelling in the legs or arms (peripheral edema)
- Cough
- Low blood pressure during dialysis
- Abdominal pain (in people on chemotherapy)
- Injection site pain and rash (reported in children)
When to get medical help
- Chest pain, sudden weakness or numbness, trouble speaking, or confusion can signal a heart attack or stroke. Get emergency help.
- Leg or arm swelling, pain or warmth, or sudden shortness of breath can signal a blood clot. Get medical help.
- If you have dialysis access, tell your care team about clotting or other problems at the site.
- Seizures or a change in seizure pattern, especially if you have chronic kidney disease, need prompt attention.
- Severe tiredness and paleness that worsens during treatment may signal pure red cell aplasia (the body stops making red blood cells). Call your doctor.
- Hives, trouble breathing, or facial swelling can signal a serious allergic reaction. Get emergency help.
- A severe skin reaction needs prompt medical care, and Aranesp should be stopped.
- Very high blood pressure needs to be reported right away.
Warnings and Precautions
- Heart attack, stroke, blood clots and death: the risk rises when hemoglobin is pushed above 11 g/dL, especially in chronic kidney disease.
- Cancer: ESAs can shorten survival or increase tumor growth or return.
- High blood pressure: it should be controlled before and during treatment.
- Seizures: risk is increased in chronic kidney disease.
- Pure red cell aplasia: if severe anemia develops, the drug is withheld and checked.
- Allergic and severe skin reactions: Aranesp is stopped.
Before You Start
- Uncontrolled high blood pressure: you should not use it.
- Pure red cell aplasia after Aranesp or similar drugs: you should not use it.
- Serious allergic reaction to Aranesp: you should not use it.
- Heart disease or prior stroke: use caution.
- Cancer: discuss the risks with your doctor.
- Latex sensitivity: the prefilled syringe needle cover contains dry natural rubber.
- Pregnancy: data are limited, so benefits and risks are weighed.
- Breastfeeding: effects on milk and the baby are unknown.
- Children: studied in kidney disease from 1 month to 16 years, but not established in cancer.
- Older adults: no differences in safety or effectiveness were seen.
Overdose
Too much Aranesp can push hemoglobin above the desired level. Severe high blood pressure has been seen after ESA overdose. Management includes stopping or lowering the dose and/or removing blood (phlebotomy), as your doctor decides.
Half-Life and How Your Body Processes It
Given into a vein, Aranesp has a terminal half-life of about 21 hours in people on dialysis, about 3 times longer than epoetin alfa. Under the skin it is absorbed slowly, peaking at about 48 hours in kidney disease. Its half-life is about 46 hours in people on dialysis and about 70 hours in those not on dialysis. Under the skin, about 37% reaches the bloodstream in adults on dialysis. In people with cancer, the half-life averages about 74 hours.
Storage
Store at 36°F to 46°F (2°C to 8°C). Do not freeze. Protect from light; store Aranesp in the carton until use.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Darbepoetin Alfa Injection Drug Interactions
Darbepoetin Alfa Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Darbepoetin Alfa Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What is Aranesp used for?
How long does Aranesp take to work?
Why do I need regular blood tests on Aranesp?
What side effects should I expect and which ones need a call?
Can I give Aranesp to myself at home?
Is Aranesp safe in pregnancy?
Is darbepoetin alfa injection available over the counter?
When was darbepoetin alfa injection first available?
What is the brand name of darbepoetin alfa injection?
What is the generic name of Aranesp?
What drug class is darbepoetin alfa injection?
What strengths does darbepoetin alfa injection come in?
How much does darbepoetin alfa injection cost?
Where can I read the darbepoetin alfa injection prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Darbepoetin Alfa Injection
Skip the scrolling. Ask in your own words and get an answer from Darbepoetin Alfa Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Darbepoetin Alfa Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Darbepoetin Alfa Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, usually within a day.Darbepoetin Alfa Injection Forms and Strengths (How It Comes)
Darbepoetin Alfa Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Darbepoetin Alfa Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Aranesp treats anemia from chronic kidney disease, in people on dialysis and not on dialysis.
- Aranesp treats anemia from chemotherapy in people with non-myeloid cancers with at least two more months of chemotherapy planned.
- Aranesp for chronic kidney disease can be given into a vein or under the skin. The intravenous route is recommended for people on hemodialysis.
- Aranesp for chemotherapy-related anemia is given under the skin.
- Aranesp should not be shaken, frozen, or mixed with other drug solutions, and should be protected from light.
- Aranesp prefilled syringes can be self-administered only after training. Vials may be considered if measuring the dose is hard.
Show 8 more strengths Show fewer strengths
Darbepoetin Alfa Injection on the U.S. Market: Products, Makers and Brands
How Darbepoetin Alfa Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 14 Darbepoetin Alfa Injection product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 2001. The one brand name in the directory today is Aranesp; the rest are generics.
How Widely Darbepoetin Alfa Injection Is Used (Medicaid Data)
How many Darbepoetin Alfa Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Darbepoetin Alfa Injection prescribed? Of the 1,682 medications we measure, Darbepoetin Alfa Injection ranks #652 by Medicaid prescriptions — more than 61% of them.
Utilization by Darbepoetin Alfa Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
0.4 ML darbepoetin alfa 0.1 MG/ML Prefilled Syringe Most dispensed
1 of 2 listed NDCs had Medicaid claims. RxNorm 731181
0.42 ML darbepoetin alfa 0.06 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 731176
0.4 ML darbepoetin alfa 0.025 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 1605171
0.3 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 731167
1 ML darbepoetin alfa 0.025 MG/ML Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 349273
0.4 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe
1 of 1 listed NDCs had Medicaid claims. RxNorm 731174
0.6 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe
1 of 1 listed NDCs had Medicaid claims. RxNorm 731179
0.5 ML darbepoetin alfa 0.2 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 730044
1 ML darbepoetin alfa 0.1 MG/ML Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 349276
1 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe
1 of 1 listed NDCs had Medicaid claims. RxNorm 731184
1 ML darbepoetin alfa 0.04 MG/ML Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 349274
1 ML darbepoetin alfa 0.06 MG/ML Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 349275
1 ML darbepoetin alfa 0.2 MG/ML Injection
1 of 2 listed NDCs had Medicaid claims. RxNorm 1654954
0.3 ML darbepoetin alfa 0.5 MG/ML Prefilled Syringe
1 of 2 listed NDCs had Medicaid claims. RxNorm 731171
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 14 of the 25 listed Darbepoetin Alfa Injection NDCs had Medicaid claims.
Compare Darbepoetin Alfa Injection Products
A representative set of FDA-listed product records for Darbepoetin Alfa Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 10 mcg/0.4 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 25 mcg/0.42 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 25 mcg/mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 40 mcg/0.4 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 40 mcg/mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 60 mcg/0.3 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 60 mcg/mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 100 mcg/0.5 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 100 mcg/mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 150 mcg/0.3 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 200 mcg/0.4 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 200 mcg/mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 300 mcg/0.6 mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
| 500 mcg/mL | Intravenous, Subcutaneous | Amgen, Inc | BLA | View NDC → |
Showing 14 of 14 products — FDA National Drug Code Directory. See every product, package size and price: browse all 14 Darbepoetin Alfa Injection NDCs →
Darbepoetin Alfa Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Darbepoetin Alfa Injection — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Darbepoetin Alfa Injection are death, hospitalisation, anaemia; about 89% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Darbepoetin Alfa Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Darbepoetin Alfa Injection FDA Approval History
How Darbepoetin Alfa Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Darbepoetin Alfa Injection was first approved by the FDA in 2001 (Brand: ARANESP · Amgen). It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Darbepoetin Alfa Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Darbepoetin Alfa recalls since July 2021.
✅No Darbepoetin Alfa recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Darbepoetin Alfa Injection in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 3
- Strengths
- 16
- Forms in current FDA listings
- 3 of 3
RxCUI 283838 -
Dose form (SCDF) Injectable SolutionIn current FDA listings
RxCUI 378604Its strength (SCD)-
0.5 mg/mL
RxCUI 403943
-
0.5 mg/mL
-
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1654923Its 6 strengths (SCD)-
0.75 mL darbepoetin alfa 0.2 mg/mL
RxCUI 1654949 -
1 mL darbepoetin alfa 0.025 mg/mL
RxCUI 349273 -
1 mL darbepoetin alfa 0.04 mg/mL
RxCUI 349274 -
1 mL darbepoetin alfa 0.06 mg/mL
RxCUI 349275 -
1 mL darbepoetin alfa 0.1 mg/mL
RxCUI 349276 -
1 mL darbepoetin alfa 0.2 mg/mL
RxCUI 1654954
-
0.75 mL darbepoetin alfa 0.2 mg/mL
-
Dose form (SCDF) Prefilled SyringeIn current FDA listings
RxCUI 730043Its 9 strengths (SCD)-
0.3 mL darbepoetin alfa 0.2 mg/mL
RxCUI 731167 -
0.3 mL darbepoetin alfa 0.5 mg/mL
RxCUI 731171 -
0.4 mL darbepoetin alfa 0.025 mg/mL
RxCUI 1605171 -
0.4 mL darbepoetin alfa 0.1 mg/mL
RxCUI 731181 -
0.4 mL darbepoetin alfa 0.5 mg/mL
RxCUI 731174 -
0.42 mL darbepoetin alfa 0.06 mg/mL
RxCUI 731176 -
0.5 mL darbepoetin alfa 0.2 mg/mL
RxCUI 730044 -
0.6 mL darbepoetin alfa 0.5 mg/mL
RxCUI 731179 -
1 mL darbepoetin alfa 0.5 mg/mL
RxCUI 731184
-
0.3 mL darbepoetin alfa 0.2 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Darbepoetin Alfa Injection Supply and Shortage Status
Whether Darbepoetin Alfa Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Darbepoetin Alfa Injection Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Darbepoetin Alfa Injection: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
How the Pharmacy Price Has Changed
Pick a strength to see how its price has changed since Apr 2024.
For brand-name Aranesp, the 25 mcg/0.42 mL injection, pharmacies paid an average of $446.91 per mL as of Nov 18, 2026, up 0.1% from $446.32 a year earlier.
- What pharmacies pay now
- $446.91
- per mL, as of Nov 18, 2026
- Last 4 weeks
- No change
- from $446.91 on Oct 21, 2026
- Last 12 months
- Up 0.1%
- from $446.32 on Nov 19, 2025
- Lowest and highest since Apr 2024
- $443.50 to $449.89
- per mL
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $446.91 |
| Oct 2026 | $446.91 |
| Sep 2026 | $446.58 |
| Aug 2026 | $447.05 |
| Jul 2026 | $447.25 |
| Jun 2026 | $448.41 |
| May 2026 | $449.89 |
| Apr 2026 | $448.64 |
| Mar 2026 | $449.89 |
| Feb 2026 | $449.89 |
| Jan 2026 | $449.89 |
| Dec 2025 | $448.74 |
| Nov 2025 | $446.32 |
| Oct 2025 | $446.32 |
| Sep 2025 | $446.32 |
| Aug 2025 | $445.28 |
| Jul 2025 | $445.28 |
| Jun 2025 | $445.29 |
| May 2025 | $444.45 |
| Apr 2025 | $444.45 |
| Mar 2025 | $443.50 |
| Feb 2025 | $444.45 |
| Jan 2025 | $443.50 |
| Dec 2024 | $446.87 |
| Nov 2024 | $446.87 |
| Oct 2024 | $446.87 |
| Sep 2024 | $446.87 |
| Aug 2024 | $446.87 |
| Jul 2024 | $446.87 |
| Jun 2024 | $446.82 |
| May 2024 | $446.82 |
| Apr 2024 | $446.50 |
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Injection · Intravenous, Subcutaneous | 25 mcg/0.42 mL | Aranesp (brand) | $446.91 per mL | NDC details & price history |
| Injection · Intravenous, Subcutaneous | 25 mcg/mL | Aranesp (brand) | $186.12 per mL | NDC details & price history |
| Injection · Intravenous, Subcutaneous | 40 mcg/0.4 mL | Aranesp (brand) | $752.44 per mL | NDC details & price history |
| Injection · Intravenous, Subcutaneous | 60 mcg/0.3 mL | Aranesp (brand) | $1,500.15 per mL | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Darbepoetin Alfa Injection Brand Names
Darbepoetin Alfa Injection has one brand name on record: Aranesp. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Darbepoetin Alfa Injection: Manufacturers and Labelers
One company lists Darbepoetin Alfa Injection products with the FDA. By number of product records, the largest are Amgen, Inc. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Darbepoetin Alfa Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Amgen Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →